Q-omics provides the consensus-scored MIR8062 profile across patient tissues and cancer cell-line models. MIR8062 expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR8062 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR8062 RNA expression shows 6,177 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ESCA, KIRC, and COAD as cancer lineages where MIR8062 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8062 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8062 survival associations across molecular data types. MIR8062 RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8062 RNA expression–survival associations across cancer types. High MIR8062 expression shows unfavorable associations in ESCA, SKCM, LAML and BRCA. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR8062 RNA expression.
This table summarizes MIR8062 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8062. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8062 shows higher tumor expression in KIRC. The KIRC box plot shows higher MIR8062 RNA expression in tumor versus normal tissue (log2 FC = +0.069, t-test p = .019).
This table shows molecular features associated with MIR8062 in patient tissues and cancer cell lines. In patient samples, MIR8062 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
